BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29722428)

  • 1. Futility of current urine salbutamol doping control.
    Heuberger JAAC; van Dijkman SC; Cohen AF
    Br J Clin Pharmacol; 2018 Aug; 84(8):1830-1838. PubMed ID: 29722428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.
    Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Clin J Sport Med; 2012 Mar; 22(2):140-5. PubMed ID: 22388343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
    Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
    Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine concentrations of oral salbutamol in samples collected after intense exercise in endurance athletes.
    Hostrup M; Kalsen A; Auchenberg M; Rzeppa S; Hemmersbach P; Bangsbo J; Backer V
    Drug Test Anal; 2014 Jun; 6(6):528-32. PubMed ID: 24166762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
    Courlet P; Buclin T; Biollaz J; Mazzoni I; Rabin O; Guidi M
    CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):469-481. PubMed ID: 35315251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
    Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
    Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
    Ventura R; Segura J; Bergés R; Fitch KD; Morton AR; Berruezo S; Jiménez C
    Ther Drug Monit; 2000 Jun; 22(3):277-82. PubMed ID: 10850394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enigma of inhaled salbutamol and sport: unresolved after 45 years.
    Fitch KD
    Drug Test Anal; 2017 Jul; 9(7):977-982. PubMed ID: 28294577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled salbutamol and doping control: effects of dose on urine concentrations.
    Sporer BC; Sheel AW; Taunton J; Rupert JL; McKenzie DC
    Clin J Sport Med; 2008 May; 18(3):282-5. PubMed ID: 18469572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ethnicity, gender, and dehydration on the urinary excretion of inhaled salbutamol with respect to doping control.
    Dickinson J; Hu J; Chester N; Loosemore M; Whyte G
    Clin J Sport Med; 2014 Nov; 24(6):482-9. PubMed ID: 24518370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine concentrations of repetitive doses of inhaled salbutamol.
    Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
    Int J Sports Med; 2011 Aug; 32(8):574-9. PubMed ID: 21563035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
    Schweizer C; Saugy M; Kamber M
    Clin J Sport Med; 2004 Sep; 14(5):312-5. PubMed ID: 15377972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
    Bergés R; Segura J; Ventura R; Fitch KD; Morton AR; Farré M; Mas M; de La Torre X
    Clin Chem; 2000 Sep; 46(9):1365-75. PubMed ID: 10973867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
    Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
    Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and urinary concentrations of salbutamol in asthmatic subjects.
    Elers J; Pedersen L; Henninge J; Lund TK; Hemmersbach P; Dalhoff K; Backer V
    Med Sci Sports Exerc; 2010 Feb; 42(2):244-9. PubMed ID: 19927035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta2-Agonist Doping Control and Optical Isomer Challenges.
    Jacobson GA; Fawcett JP
    Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography-tandem mass spectrometry.
    Mareck U; Guddat S; Schwenke A; Beuck S; Geyer H; Flenker U; Elers J; Backer V; Thevis M; Schänzer W
    Drug Test Anal; 2011; 3(11-12):820-7. PubMed ID: 22081503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification and stability of salbutamol in human urine.
    Forsdahl G; Gmeiner G
    J Sep Sci; 2004 Jan; 27(1-2):110-4. PubMed ID: 15335066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the relative bioavailability of salbutamol to the lung following inhalation.
    Hindle M; Chrystyn H
    Br J Clin Pharmacol; 1992 Oct; 34(4):311-5. PubMed ID: 1457264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged.
    Silkstone VL; Tomlinson HS; Corlett SA; Chrystyn H
    Br J Clin Pharmacol; 2000 Sep; 50(3):281-4. PubMed ID: 10971315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.